FIRST AMENDMENT TO THEDevelopment and Option Agreement • August 5th, 2020 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledAugust 5th, 2020 Company IndustryThis First Amendment (the “First Amendment”) to the Development and Option Agreement dated November 20, 2019 (the “Agreement”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), and AbbVie Biotechnology Ltd, a Bermuda corporation (“AbbVie”) is made effective as of the date of the final signature to this First Amendment. Harpoon and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractHarpoon Therapeutics, Inc. • August 5th, 2020 • Biological products, (no disgnostic substances) • Delaware
Company FiledAugust 5th, 2020 Industry JurisdictionCERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.